Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Di Tanna, Gian Luca; Porter, Joshua K.; Lipton, Richard B.; Hatswell, Anthony J.; Sapra, Sandhya; Villa, Guillermo

doi:10.1186/s12955-019-1242-6

Table 4 Regression outputs mapped from HIT-6 (N = 10,971)

From: Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Utility values mapped from HIT-6	Linear mixed effects model with REML				Fractional response model (logit)				Fractional response model (probit)				Beta regression
Utility values mapped from HIT-6	Coeff	95% CI		p value	Coeff	95% CI		p value	Coeff	95% CI		p value	Coeff	95% CI		p value
Erenumab 70 mg (vs placebo)	0.007	−0.002	0.016	0.151	0.037	−0.013	0.870	0.148	0.022	−0.008	0.052	0.143	0.032	−0.058	0.123	0.484
Erenumab 140 mg (vs placebo)	0.020	0.009	0.030	< 0.001	0.112	0.053	0.171	< 0.001	0.067	0.032	0.101	0.0002	0.202	0.076	0.328	0.002
Baseline MMD	0.0002	−0.001	0.001	0.618	0.010	0.004	0.016	0.001	0.005	0.002	0.009	0.003	0.045	0.034	0.057	< 0.001
MMD	−0.012	−0.013	− 0.012	< 0.001	−0.070	−0.075	−0.065	< 0.001	−0.042	−0.045	−0.039	< 0.001	−0.096	−0.107	−0.086	< 0.001
Visit
Week 4	0.032	0.028	0.037	< 0.001	0.149	0.125	0.174	< 0.001	0.089	0.074	0.104	< 0.001	0.149	0.086	0.211	< 0.001
Week 8	0.040	0.036	0.045	< 0.001	0.195	0.166	0.223	< 0.001	0.116	0.099	0.133	< 0.001	0.244	0.173	0.316	< 0.001
Week 12	0.043	0.038	0.048	< 0.001	0.210	0.180	0.240	< 0.001	0.124	0.107	0.142	< 0.001	0.249	0.178	0.321	< 0.001
Week 16	0.03	0.046	0.059	< 0.001	0.312	0.266	0.357	< 0.001	0.181	0.155	0.208	< 0.001	0.512	0.402	0.621	< 0.001
Week 20	0.050	0.044	0.057	< 0.001	0.306	0.260	0.353	< 0.001	0.178	0.151	0.205	< 0.001	0.529	0.411	0.647	< 0.001
Week 24	0.050	0.044	0.056	< 0.001	0.309	0.261	0.356	< 0.001	0.180	0.152	0.207	< 0.001	0.472	0.369	0.574	< 0.001
Age	0.0007	0.0003	0.001	< 0.001	0.004	0.002	0.006	< 0.001	0.002	0.001	0.004	< 0.001	0.006	0.001	0.010	0.010
Female	−0.023	0.034	−0.012	< 0.001	−0.135	−0.201	−0.069	< 0.001	−0.080	−0.118	−0.041	< 0.001	−0.128	−0.252	− 0.004	0.042
Race (vs white)
Black	−0.014	−0.030	0.003	0.101	−0.061	−0.155	0.033	0.203	−0.036	−0.091	0.019	0.198	0.021	−0.149	0.191	0.810
Other	−0.003	−0.028	0.227	0.829	−0.016	−0.178	0.145	0.845	−0.008	−0.865	0.086	0.865	0.244	−0.133	0.622	0.205
RMSE	0.112				0.113				0.113				0.118
MAE	0.087				0.088				0.088				0.089

Abbreviations: CI confidence interval, Coeff coefficient, HIT-6 Headache Impact Test, MAE mean absolute error, MMD monthly migraine day, MSQ Migraine-Specific Quality of Life Questionnaire, REML restricted maximum likelihood, RMSE root mean squared error

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us